Withdrawal symptoms · management of opium withdrawal
4 findings from 1 review
Show 1 more finding
no estimate extracted
34 participants
Very low
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Clinical resolution · acute infectious diarrhoea in children
Smectite may leads to higher clinical resolution at day 3 compared with control (low certainty).
1 finding from 1 review
Patient or carer satisfaction with information provided CCFNI (between day 3 and day 5); scale from 14 to 56 Lower scores indicate increased satisfaction. FS‐ICU 24 (90 days after randomisation); scale from 0 to 100 Lower scores indicate less sati... · adult ICU patients and their carers
1 finding from 1 review
Pain postoperative day 3 № of participants: 401 (5 studies) · patients requiring tonsillectomy (any diagnosis)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Serum creatinine: day 3 · patients undergoing a surgical intervention that induces kidney injury
1 finding from 1 review
no estimate extracted
Studies not reported
High
Frequency of breastfeeding per day · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Weight loss (%) day 3 (percentage of birthweight) · healthy breastfeeding full‐term infants
1 finding from 1 review
Mortality at day 30 · AKI
Intensive showed no clear difference in mortality at day 30 compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Clinical severity score (day 3) · children with acute bronchiolitis
1 finding from 1 review
Oxygen efficiency (PaO2/FiO2) day 3 postoperative · adult participants given general anaesthesia
1 finding from 1 review
Intervention not reported
Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Pain subsequent to donation ("after collection" ‐ day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Score (MMS) day 30
1 finding from 1 review
Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review